Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Oct 29, 2024 · 10-Q · 29 days after period end · 0001808805-24-000072
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$16.45M | -$15.88M | -$14.06M | -$14.50M |
| EPS Diluted | -$0.13 | -$0.13 | -$0.11 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Oct 29, 2024 · 29 d after period end
